Croívalve Ltd. secured a further $20 million in series B financing for its Duo Adapt system, a transcatheter device that treats tricuspid regurgitation. The company also received $7 million from the European Innovation Council and the Disruptive Technologies Innovation Fund in grant financing. Croívalve will use the funds to expand its clinical study, which is evaluating the safety and performance of the Duo Adapt system in patients with severe or greater symptomatic tricuspid regurgitation.
Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Airs Medical, Gero AI, Multivalent Biotherapies, Coherent, Racura Oncology.
Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer improvements over existing classes of monoclonal antibodies for treating chronic inflammatory diseases.
Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using Replicate’s clinically validated self-replicating RNA (srRNA) platform.
Scribe Therapeutics Inc. has been awarded more than $25 million by California Institute for Regenerative Medicine (CIRM) across two preclinical programs for CRISPR-based gene editing therapies targeting cardiovascular and metabolic disease.
Biopharma and med-tech companies raising money in public or private financings, including: Adaptive, Airs, Bioaffinity, Chugai, Dyne, Gero, Neogenomics, Roche, Sophia, Triveni, Vedana, Wise.
Cardiovascular-focused Kardigan Inc. is the latest biopharma firm to take advantage of the wide open IPO window, pricing an upsized offering of 25 million shares at $16 per share, the high end of its proposed range, to rake in gross proceeds of about $400 million.
RSS
